Kornimate/medical-research-clean huggingface dataset:
to evaluate the efficacy and safety of "rongyang zhengyifang" tea bag with covid-19 variant virus

Conditions: Herbal Interaction

Summary: the strategy of our study is to use traditional chinese medicine tea to regulate physical fitness and strength can be enhanced to help patients with mildly diagnosed covid-19 variant virus to achieve self-recovery ability and avoid the development of moderate and severe symptoms.

according to the "interim guidelines for the clinical treatment of novel coronavirus sars-cov-2 infection" published by the cdc of the ministry of health and welfare on june 23, 2021, it can be classified into mild, moderate, severe and extremely severe according to the classification of its related clinical manifestations. current clinical studies have found that covid-19 primarily attacks the bronchioles and alveoli of the lower respiratory tract. in severe cases, it may induce an inflammatory response, leading to pulmonary airway and alveolar damage, and even pulmonary fibrosis. the strategy of our study is to use traditional chinese medicine tea to regulate physical fitness and strength can be enhanced to help patients with mildly diagnosed covid-19 variant virus to achieve self-recovery ability and avoid the development of moderate and severe symptoms.it may reduce the expenditure of health insurance and medical expenses, and more importantly, if it can be administered timely to block the progression of the disease when mild-to-moderate symptoms occur, it can also reduce the burden of hospital medical care.

Eligibility criteria:
inclusion criteria: * aged over 20 years old, according to the guidelines of the epidemic command center, during home isolation and self-epidemic prevention or home quarantine period, use the home novel coronavirus antigen rapid screening reagent to test positive, and after the medical staff confirms the relevant symptoms or the pcr test is positive, it is determined as those who were mildly diagnosed and who did not use antiviral drugs were given tea immediately. exclusion criteria: * patient characteristics: exclude women under the age of 20, incapacitated, pregnant or breastfeeding * disease characteristics: subjects who have been diagnosed with mental illness by western medicine, and who have long-term diarrhea or long-term use of traditional chinese medicine * environmental characteristics: other conditions that prevent the patient from cooperating. such as being unsuitable after screening, not signing the subject's consent form, etc.
a clinical study of efinopegdutide in participants with precirrhotic nonalcoholic steatohepatitis (nash) (mk-6024-013)

Conditions: Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis

Summary: the purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (nash). researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. the main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of nash without liver scarring getting worse.


Eligibility criteria:
inclusion criteria: * histological confirmation of nash, defined as nafld activity score (nas) ≥4 with a score ≥1 point in each component (steatosis, ballooning, and lobular inflammation) and nash clinical research network (crn) fibrosis score of stage 2 or 3 * no history of type 2 diabetes mellitus (t2dm) or a history of t2dm with an a1c ≤9% that is controlled by diet or stable doses of antihyperglycemic agents (ahas) * participants in south korea are eligible between the ages of 19 to 80 years of age (inclusive) exclusion criteria: * history of liver disease other than nash * history or evidence of cirrhosis * history of pancreatitis * history of type 1 diabetes mellitus (t1dm), diabetic ketoacidosis, or diabetes secondary to pancreatectomy * history of a bariatric surgical procedure ≤5 years before study entry, or a known clinically significant gastric emptying abnormality * has significant systemic or major illnesses, including recent events (≤6 months before study entry) of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack
augmented reality for behavior and executive function of children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the aim of the study is to determine the effects of usage of augmented reality for restricted and repetitive behavior and executive function of children with autism spectrum disorder

augmented reality allows children to see a representation of imaginary content and pretend play overlaid on the real-world environment. today, technology can be a safe and motivating way of engaging children with autism in social interaction activities. current research in therapeutic technology for autism is aimed toward improving behavior and psychomotor activities that impact social communication. the aim of this research project is to help teachers, parents, practitioners, and researchers to understand the unique strengths of their children with autism along with technology based educational and therapeutic activities for home and classroom.

Eligibility criteria:
inclusion criteria: * participants diagnosed with autism spectrum disorder in the age range of 5-12 years at verbal imitation and 1-step command following. exclusion criteria: * sensory issues and patients on medication

Keywords: augmented reality behaviour executive function
benefit of cfae ablation

Conditions: Persistent Atrial Fibrillation

Summary: the optimal strategy for catheter ablation of persistent atrial fibrillation is not clearly defined. this study investigates if complex fractionated atrial electrogram (cfae) ablation in addition to pulmonary vein isolation and linear ablations improves single procedural success rate over a 12 month follow up period.


Eligibility criteria:
inclusion criteria: * persistent atrial fibrillation exclusion criteria: * previous catheter or surgical ablation for atrial fibrillation * pregnancy

Keywords: catheter ablation atrial fibrillation pulmonary vein isolation linear ablation cfae ablation
phase 1, single and repeat dose study to assess safety, tolerability, and pharmacokinetics (pk) of gsk3923868 in participants with chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this is a two parts study, a single ascending dose followed by 14-days repeat dosing. the single ascending dose part will assess two dose levels of gsk3923868 or placebo across two treatment periods 1 and 2 in a single cohort of participants with a washout period of a minimum of 5 days after each treatment periods. the repeat dose part will assess repeated one dose level of gsk3923868 or placebo in treatment period 3 with up to 14 days of follow up in the same cohort of participants. the duration of study participation for treatment period 1, 2 and 3 will be 6, 6 and up to 29 days (including follow up), respectively.


Eligibility criteria:
inclusion criteria: * between 40 and 70 years of age. * confirmed diagnosis of copd for greater than (\>) 6 months. * participant is a smoker or an ex-smoker with a smoking history of at least 10 pack years. * a female participant is eligible to participate if she is not pregnant or breastfeeding and agrees to use contraceptives during the study (for women of childbearing potential only). exclusion criteria: * participant has poorly controlled or unstable copd. * participant has a past or current medical condition(s) or disease(s) that is/are not well controlled. * participant has had a respiratory tract infection treated with antibiotics within 4 weeks prior to screening. * participant requires regular treatment with oral corticosteroids or has received a course of oral or parenteral corticosteroids within 4 weeks prior to screening. * participant requires long-term oxygen therapy. * current enrolment or past participation in a clinical trial within 30 days before this study starts. * positive tests for human immunodeficiency virus (hiv), hepatitis b and c, or coronavirus disease-19 (covid-19). * positive pre-study drug (except for as results of opioids prescribed for medical reasons and/or inadvertent consumption of poppy seeds) /alcohol screening result.

Keywords: single ascending dose repeat dose phosphatidylinositol 4-kinase beta (pi4kb) inhibitor chronic obstructive pulmonary disease (copd)
comparison of pilates &home exercise programs on muscle strength in paraplegic patients

Conditions: Spinal Cord Injuries

Summary: paraplegic patients to be included in the study were divided into 2 groups by randomization and it was planned to apply reformer pilates or home exercise programs for 8 weeks. it was aimed to compare upper extremity muscle strengths, spinal cord independence measure version iii (scim-iii) and the short form(36) health survey (sf-36) data before and after treatment.

spinal cord injuries (sci) are injuries that occur as a result of compression, incision or contusion of the spinal cord, which extends from foramen magnum to cauda equina.these patients experience various complications and organ system damage in the chronic period.their self-dependence is affected by the level of injury. one of the most important factors affecting the self-dependence of people with sci is the strength of the upper extremity.strong upper extremities are needed for independent transfer from bed. sci patients member of turkish spinal cord injury association, according to the criteria for inclusion in the study patient list was created. in accordance with the sample size with the random numbers prepared with a computer program from this list, 18 people were planned to be included in the study. the patients were planned to be randomly divided into the study and control groups.reformer pilates was planned, suitable for the disabled, with an instructor for the patients in the study group for 8 weeks; a home exercise program with telephone monitoring was planned for the patients in the control group for 8 weeks.it was planned to record the demographic data of the patients (age, gender, occupation, additional disease).it was planned to fill the sf-36 form to measure the quality of life of the patients, scim-iii forms to evaluate functionally and measure the upper extremity muscle strength with a hand dynamometer. at the end of 8 weeks, the patients were called for an examination, and sf-36, scim-iii forms were filled and muscle strength was measured, and the comparison was aimed within the group and between the groups.in our study, our aim is to demonstrate the applicability of the reformer pilates program in sci patients. in addition, to show the effects of home exercise program and reformer pilates programs on upper extremity muscle strength in sci patients with multiple comparison tests.

Eligibility criteria:
inclusion criteria: * volunteering for study * lesion level: t2 and below diagnosed with sci * lesion duration over 2 years * ambulation in wheelchair * to ensure randomization, sci patients must be a member of turkish spinal cord injury association and which should not be included in any study group. exclusion criteria: * severe psychiatric disorder * general condition disorder (heart failure, lung failure) * intolerably shoulder pain during exercise

Keywords: spinal cord injuries reformer pilates home exercise
gene therapy for x-linked retinitis pigmentosa (xlrp) - retinitis pigmentosa gtpase regulator (rpgr)

Conditions: X-Linked Retinitis Pigmentosa

Summary: phase 1 of the study is a dose escalation of the subretinal administration of aav5-hrkp.rpgr vector to assess the safety of this vector in participants with xlrp caused by mutations in rpgr. participants enrolled in phase 1 were assigned to a dose group based on when they enrolled (i.e., sequential assignment). phase 2 of the study is a cohort expansion of the subretinal administration of aav5-hrkp.rpgr vector to assess the safety and efficacy of this vector in participants with xlrp caused by mutations in rpgr. participants enrolled in phase 2 were randomized to immediate or deferred treatment.

this is an open-label phase 1/2 dose-escalation and cohort expansion trial to determine the safety and efficacy of subretinal administration of aav5-hrkp.rpgr vector in participants with xlrp caused by mutations in rpgr.

Eligibility criteria:
key inclusion criteria: * males aged 5 years or older * have x-linked retinitis pigmentosa confirmed by a retinal specialist (ci or pi) key exclusion criteria: • have participated in another research study involving an investigational medicinal therapy for ocular disease within the last 6 months

Keywords: xlrp rpgr
carotene and retinol efficacy trial

Conditions: Lung Cancer

Summary: the carotene and retinol efficacy trial (caret) was a randomized, double-blind, placebo-controlled trial of the cancer prevention efficacy and safety of a daily combination of 30 mg of beta-carotene and 25,000 iu of retinyl palmitate in 18,314 persons at high risk for lung cancer. caret began in 1985, and the intervention was halted in january 1996, 21 months ahead of schedule, with the twin conclusions for definitive evidence of no benefit and substantial evidence of a harmful effect of the intervention on both lung cancer incidence and total mortality. caret continued to follow and collect endpoints on their participants through 2005. during the active intervention phase of caret, serum, plasma, whole blood, and lung tissue specimens were collected on participants. these biospecimens make up the caret biorepository. the caret biorepository is a valuable resource for population-based studies of the major human cancers. during caret's twenty years of follow-up (1985-2005), we have received reports of 1,445 participants with lung cancer, 901 with prostate cancer, 433 with breast cancer, 334 with bladder cancer, 332 with colon cancer, and 1,429 with other cancers. caret is one of the few trials that has prospectively collected serum, plasma, whole blood, blood spots (for dna), and lung cancer tumor specimens, as well as smoking history and serial food frequency questionnaires (in some individuals for up to 12 years) in populations at high risk for lung cancer. this wealth of information in over 18,000 individuals makes the caret biorepository a special resource for cancer researchers.


Eligibility criteria:
inclusion criteria: * asbestos-exposed men who were: * current smokers or quit within 15 years prior to enrollment * had first exposure to asbestos on the job at least 15 years prior to enrollment * had chest x-ray positive for changes compatible with asbestos exposure according to ilo criteria; or had been employed in a protocol-defined high-risk trade for at least 5 years, at least 10 years prior to enrollment. * heavy smokers, men and women: * cigarette smoking history of 20+ pack-years * either current smokers or had quit within previous 6 years exclusion criteria: * pre-menopausal women * history or cirrhosis or hepatitis within 12 months prior to enrollment * taking \> 5500 iu daily vitamin a supplement * taking any beta-carotene supplement * history of cancer within 5 years prior to enrollment * sgot \> than 2.5x upper limit of normal, or alkaline phosphatase \> 1.5x upper limit of normal * taking less than 50% of study vitamins during the enrollment period between the first and second visits.
preop conformal radiotherapy - prostate

Conditions: Prostatic Neoplasm

Summary: radical prostatectomy and radical radiation therapy remain the standard treatment approaches for patients with clinically localized prostate cancer (t1, t2).radical prostatectomy is most effective when the disease is organ confined at the time of surgery. however, in many series up to 60% of patients have positive resection margins at the time of surgery and there is evidence to suggest that these patients may not be curable by surgery alone. a number of preoperative clinical variables including clinical stage, serum prostate specific antigen (psa) and gleason scorea re helpful in determining the probability of finding organ confined disease at the time of syrgery.


Eligibility criteria:
* histologically confirmed carcinoma of the prostate * high risk localized disease defined as clinical t1 or t2 plus \[ (i) gleason ¡ý7, psa\>10 ng/ml and \ 15 ng/ml and less \<35 ng/ml (any gleason) \] * no evidence of pelvic lymph node metastases on ct scan within 4 months of surgery * no evidence of distant metastases on bone scan within 4 months of surgery * no contraindication to pelvic radiation therapy
biosimilar retacrit™ (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anaemia in haematology and oncology

Conditions: Chemotherapy-induced Symptomatic Anaemia; Solid Tumours; Malignant Lymphomas; Multiple Myeloma

Summary: the purpose of this study is to observe correction of haemoglobin (hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with retacrit™.

this is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study in adult patients who are suffering from cancer or malignant blood disease and whose chemotherapy treatment has induced symptomatic anaemia and being treated with retacrit® to correct haemoglobin levels.

Eligibility criteria:
inclusion criteria: * patients age ≥18 years . * patients present with chemotherapy-induced symptomatic anaemia. * patients suffer from solid tumours, malignant lymphomas or multiple myeloma and have developed symptomatic anaemia due to their chemotherapy. * the patients may be included regardless of their chemotherapy cycle (from the first cycle until the last cycle) * patients eligible for epoetin alfa biosimilar treatment. exclusion criteria: * patients are not receiving chemotherapy. * patients already included in an epoetin zeta study. * patients presenting with the contraindications to epoetin zeta. * patients presenting with the hypersensitivity to the active substance or any of the excipients. * the patient presents erythroblastopenia, or 'pure red cell aplasia' (prca). * patients with uncontrolled hypertension. * patients who cannot receive adequate prophylaxis by antithrombotic agents.

Keywords: symptomatic anameia
comparison of vt ablation outcomes using remote magnetic navigation versus manual approach in a low lvef population

Conditions: Tachycardia, Ventricular

Summary: the study purpose is to demonstrate that ventricular tachycardia (vt) ablation using the niobe™ es system results in superior outcomes compared to a manual approach in subjects with ischemic scar vt in a low ejection fraction population.

this study is a randomized, single-blind, prospective, multi-center post market evaluation. subjects will be screened for study eligibility and asked to complete written informed consent prior to any study specific testing assessments. after completing written informed consent, a total of 386 subjects will be randomized on a 1:1 basis to receive vt ablation treatment using either the niobe es or standard manual catheter ablation treatment using commercially available products. this will be the largest randomized vt study comparing outcomes from rmn to manually guided catheter ablation procedures. subjects will be randomized according to a computer-generated randomization scheme. randomization will be blocked at the study site level and subjects will be blinded to group assignment. since quality of life measurements will be collected during follow-up, this study is single-blinded in order to mitigate patient bias. clinical evaluations will not be masked to the treating physician.

Eligibility criteria:
inclusion criteria: * subject has had an icd previously implanted * subject has drug-refractory monomorphic vt * subject is a candidate for ischemic vt rf ablation * subject has had a myocardial infarction * subject has a lvef less than or equal to 35% exclusion criteria: * subject has non-ischemic vt * subject has a history of stroke within 1 month prior to enrollment * subject has had an acute myocardial infarction within 30 days prior to enrollment * subject has unstable angina * subject has undergone cardiac surgery within 60 days prior to enrollment * subject is pregnant or nursing * subject has a limited life expectancy of 1 year or less (subjects requiring lvad/iabp intraprocedural support may be enrolled as long as life expectancy is at least 1 year following the ablation procedure.) * subject is unable or unwilling to cooperate with study procedures * subject has a known presence of intracardiac thrombi as determined by echocardiography * subject has a major contraindication to anticoagulation therapy or coagulation disorder * subject has had a previous pericarditis or cardiac tumor * subject has had previous thoracic radiation therapy * any other reason the investigator considers the subject ineligible
renal cell carcinoma and stage iv inferior vena cava thrombus: resection without thoracotomy

Conditions: Renal Cell Carcinoma Stage III

Summary: assessment of short-term outcomes of radical nephrectomy combined with ivc thrombectomy with a novel technique without thoracotomy: single center case series.

assessment of the 30-day mortality and major complications as well as long-term oncological outcomes of three patients undergoing radical nephrectomy combined with inferior vena cava (ivc) thrombectomy with a novel technique without thoracotomy for renal cell carcinoma with ivc level iv thrombus. this is a retrospective case series carried out at attikon university hospital between january 2018 to march 2020.

Eligibility criteria:
inclusion criteria: * adult patients * documented radiological and/or pathological diagnosis of renal cell carcinoma with level iv tumor thrombus exclusion criteria: * american anesthesia association (asa) class v and/or any contraindications to general anesthesia

Keywords: renal cell carcinoma tumor thrombus inferior vena cava level iv